

INVESTMENT OBJECTIVE

To achieve capital appreciation on an absolute and relative basis over the medium to long-term horizon through investment in Swiss equities with a focus on innovative companies that are leaders in their markets profile.

PORTFOLIO REVIEW

During February, Swiss companies continued to report their full-year results, taking the opportunity to provide some guidance regarding the outlook for the current year. Caution is very much prevalent; in many cases no clear improvement is expected before the second half. While the strength of the Swiss franc proved a major headwind last year, it will likely continue to weigh on business in the early months of 2024, albeit to a lesser extent. To offset this burden, many companies have already introduced cost optimisation measures.

The Bruellan Swiss Equities fund gained 2.2% in February, while its Benchmark rose by 2.0%. Among the main contributors to the fund's outperformance were Alcon (+15%), Georg Fischer (+13%), Lonza (+9%) and Accelleron (+7%).

In the case of **Georg Fischer**, the rebound follows the industrial company's decision not to carry out a capital increase to finance Uponor, which it acquired last September. To ensure greater financial flexibility, the group had indeed given itself the opportunity to carry out a capital increase of up to CHF 2 billion, representing a potential dilution of some 10%, which contributed to weigh on the share price in recent weeks.

As regards eye treatment specialist **Alcon**, while results matched expectations, it was mainly the above-consensus forecasts for 2024 that were welcomed by the market. The group thus continues to generate stronger growth than its competitors and to gain market share.

Among the biggest decliners figure Also (-9%), Sandoz (-8%), Sensirion (-7%) and Nestlé (-7%). For both Also and Nestlé, these drops follow disappointing results. Although the food giant did report a slight increase in volumes after several quarters of decline, its numbers nonetheless fell short of market expectations. What's more, Nestlé does not expect any real improvement until the second half of 2024. As of the end of February, its share price was almost back to its March 2020 level.

During the quarter under review, we sold our investment in Logitech and acquired a stake in Richemont. Although Logitech reported solid results in January and was even able to increase guidance for the current year, we consider the share price upside to be limited at this stage. The forecasts for the 2024-2025 financial year that will be unveiled by the group in the coming weeks could well prove disappointing, with some caution owing to the macroeconomic backdrop. Conversely, the Richemont luxury group is exhibiting impressive resilience and once again proving the strength of its brands, particularly in the jewellery division. We saw the recent share price weakness as a good opportunity to constitute a position.

RISK & REWARD

1	2	3	4	5	6	7
---	---	---	---	---	---	---

Low High

FUND FACTS

Domicile	Luxembourg (UCITS)
Inception date	10 June 2021
Currency	CHF
Lead Manager	Anick Baud
Co-Manager	Florian Marini CFA, CMT
Fund size*	CHF 26 Millions
Liquidity (sub./red.)	Daily
Min. Investment	Instit: 1 million CHF


Management fees	0.8%
Performance fees	20%
High Water Mark	Yes
Benchmark	MSCI Switzerland 10-40
ISIN	Instit: LU2264701074

Bloomberg Instit: PRPSEIC LX

NAV Instit: 91.82

* the total strategy size is CHF 55 millions

NET PERFORMANCE AND ANNUAL PERFORMANCE IN CHF




	Fund	Bench.	+/-
1 Month	2.2%	2.0%	0.3%
3 Months	4.8%	6.6%	-1.8%
YTD	1.0%	3.3%	-2.3%
Since inception	-8.2%	0.0%	-8.2%


STATISTICS

	Fund	Bench.
Leading PE	20.6	15.7
EV/EBITDA	18.3	12.3
P/Book	4.6	1.6
Dividend Yield	2.2%	2.7%
ROE	21.0%	10.5%
Debt/Equity	49.4%	55.4%
Interest Coverage	17.6	9.6
Beta	1.1	1.0
Volatility	17.3%	13.5%

ALLOCATION BY MARKET CAP



ALLOCATION BY SECTOR



FUND COMPLEMENTARY DETAILS

Administrator	Fund Partner Solutions SA
Representative in Switzerland	FundPartner Solutions (Suisse) SA
Investment Manager	Bruellan SA
Custodian	Pictet & Cie (Europe) SA
Paying agent in Switzerland	Banque Pictet & Cie SA
Auditor	Deloitte Audit SARL

TOP 10 HOLDINGS

	Sector	Weight
NOVARTIS AG-REG	Health Care	8.7%
NESTLE SA-REG	Consumer Staples	8.5%
ROCHE HOLDING AG-GENUSSCHEIN	Health Care	6.7%
STRAUMANN HOLDING AG-REG	Health Care	4.4%
ZURICH INSURANCE GROUP AG	Financials	4.2%
CIE FINANCIERE RICHEMO-A REG	Consumer Discretionary	4.1%
SIKA AG-REG	Materials	4.0%
FISCHER (GEORG)-REG	Industrials	3.8%
SANDOZ GROUP AG	Health Care	3.7%
LONZA GROUP AG-REG	Health Care	3.6%
Total		51.8%
Total number of Holdings		27

CONTACT

BRUELLAN SA
 Rue Pécolat 1
 CH-1201 Genève
 Tél: +41 22 817 18 55
 bam@bruellan.ch

Disclaimer. This publication is a promotional document within the meaning of art. 68 LSFIn, it is not independent research. It is solely intended to provide information on the funds in question and does not constitute an offer to buy or sell, investment advice or a recommendation regarding investment or other decisions.

The funds may be subject to sales restrictions applicable to certain countries or individuals. It is the responsibility of each investor to be aware of the terms and conditions applicable to each product. This publication is directed only at persons authorised to receive it under the regulations in force in their country of domicile.

The information contained herein is based on sources believed to be reliable. However, Bruellan cannot guarantee its completeness and accuracy and accepts no liability for any damage that may result from actions taken on the basis of the information published in this document. The information reflects the situation on the day of publication.

Investment decisions should always be made on the basis of a detailed source of information, in particular the fund prospectus. The prospectus, the articles of association, the key investor information document, the subscription form and the latest annual and semi-annual reports can be obtained from the Swiss representative, Fund Partner Solutions (Suisse) SA, 60, route des Acacias, 1211 Geneva. Bruellan SA has a FINMA authorisation as a collective asset manager.